Figure 6.

UNE-C1 induces CD8⁺ T-cell-mediated antitumor immune responses and shows synergy with anti-CTLA-4 antibody. (A) After E.G7-OVA tumor-bearing mice (n=5) were immunized on days 3 and 10, the mice were injected intraperitoneally with anti-CD8, anti-CD4, and anti-NK1.1 antibodies on days 2, 5, 8, and 11. Tumor volumes were monitored and tumors were collected on day 17 to determine tumor weights. (B) C57BL/6 mice (n=12) were implanted with 1×10⁶ E.G7-OVA cells. OVA plus UNE-C1 was injected subcutaneously on days 3 and 10. Anti-CTLA-4 was injected intraperitoneally on days 3, 6, 9, 12, and 15 to check the synergy effect. Tumor volumes were measured and the percent of tumor survival is shown. Data are representative of three independent experiments. All results are presented as mean±SEM. P values of tumor volumes were calculated by Student’s t-test, and survival days were analyzed by the Mantel-Cox test (**p<0.01, ***p<0.001). OVA, ovalbumin.